Ensign Peak Advisors
DSGN icon

Ensign Peak Advisors’s Design Therapeutics DSGN Stock Holding History

Ensign Peak Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50,000
Closed -$808K – 2174
2022
Q1 		$808K Hold
50,000
– – ﹤0.01% 1321
2021
Q4 		$1.07M Hold
50,000
– – ﹤0.01% 1242
2021
Q3 		$735K Hold
50,000
– – ﹤0.01% 1532
2021
Q2 		$995K Hold
50,000
– – ﹤0.01% 1439
2021
Q1 		$1.5M Buy
+50,000
New +$1.69M ﹤0.01% 1249

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors's DSGN Position: Q2 2022 in Review

Ensign Peak Advisors sold out of Design Therapeutics (DSGN) in Q2 2022, closing a stake of 50,000 shares — an estimated $808K sold.

Ensign Peak Advisors first reported a position in DSGN in Q1 2021 and held it in 5 quarters. The position peaked at $1.5M in Q1 2021. 74 funds tracked by Wall St. Rank hold DSGN as of Q2 2022.

  • Ensign Peak Advisors reported no remaining Design Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 50,000 Design Therapeutics shares in Q2 2022, an estimated $808K.
  • Ensign Peak Advisors first reported a position in Design Therapeutics in Q1 2021 and held it in 5 quarters.
  • Ensign Peak Advisors's Design Therapeutics position peaked at $1.5M in Q1 2021.
  • 74 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2022.

Based on Ensign Peak Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.